TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.08% | 4.33% | -20.20% | -15.85% | -16.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.55% | 16.23% | -17.75% | -12.78% | -19.35% |
| Operating Income | -22.55% | -16.23% | 17.75% | 12.78% | 19.35% |
| Income Before Tax | -105.52% | -81.78% | -37.39% | -49.59% | 9.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -106.87% | -81.78% | -37.39% | -49.59% | 9.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.87% | -81.78% | -37.39% | -49.59% | 9.66% |
| EBIT | -22.55% | -16.23% | 17.75% | 12.78% | 19.35% |
| EBITDA | -22.78% | -16.83% | 17.45% | 12.56% | 19.31% |
| EPS Basic | 77.16% | -148.08% | -- | -- | -- |
| Normalized Basic EPS | 79.41% | -147.10% | -- | -- | -- |
| EPS Diluted | 77.16% | -148.08% | -- | -- | -- |
| Normalized Diluted EPS | 79.41% | -147.10% | -- | -- | -- |
| Average Basic Shares Outstanding | 7,340.00% | 11,603.14% | -- | -- | -- |
| Average Diluted Shares Outstanding | 7,340.00% | 11,603.14% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |